EUVIMEDEUVIMED entdecken
Open Access

Nerandomilast as the first PDE4B-selective therapy in idiopathic pulmonary fibrosis

Md Ibrahim, Gary A Piazza, Fakhrul Ahsan

Trends in Pharmacological Sciences · 2026-01 · 47 (1) · 120-121

DOI: 10.1016/j.tips.2025.11.006 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Trends in Pharmacological Sciences, 2026-01. Verfasst von Md Ibrahim und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical and Biomedical Sciences, College of Pharmacy, California Northstate University, Elk Grove, CA 95757, USA; Masters of Pha…. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 6 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, National Institutes of Health, National Heart Lung and Blood Institute.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

  • Department of Pharmaceutical and Biomedical Sciences, College of Pharmacy, California Northstate University, Elk Grove, CA 95757, USA; Masters of Pharmaceutical Sciences Program, College of Graduate Studies, California…
  • Drug Discovery and Development Department, Harrison College of Pharmacy, Auburn University, Auburn, AL 36849, USA; ADT Pharmaceuticals, LLC, Orange Beach, AL 31691, USA.
  • Department of Pharmaceutical and Biomedical Sciences, College of Pharmacy, California Northstate University, Elk Grove, CA 95757, USA; Veterans Affairs Northern California Health Care System, Martinez, CA 94553, USA. El…

Förderung

  • NHLBI NIH HHS
  • National Institutes of Health
  • National Heart Lung and Blood Institute
  • Cardiovascular Medical Research and Education Fund

Zitieren

APA

Ibrahim, M., Piazza, G. A., & Ahsan, F. (2026). Nerandomilast as the first PDE4B-selective therapy in idiopathic pulmonary fibrosis. Trends in Pharmacological Sciences, 47(1), 120-121. https://doi.org/10.1016/j.tips.2025.11.006

Vancouver

Ibrahim M, Piazza GA, Ahsan F. Nerandomilast as the first PDE4B-selective therapy in idiopathic pulmonary fibrosis. Trends in Pharmacological Sciences. 2026;47(1):120-121. doi:10.1016/j.tips.2025.11.006

BibTeX
@article{Ibrahim2026,
  author = {Ibrahim, Md and Piazza, Gary A and Ahsan, Fakhrul},
  title = {Nerandomilast as the first PDE4B-selective therapy in idiopathic pulmonary fibrosis},
  journal = {Trends in Pharmacological Sciences},
  year = {2026},
  volume = {47},
  number = {1},
  pages = {120--121},
  doi = {10.1016/j.tips.2025.11.006}
}
Kostenlos starten →